A “Super Vaccine” Deal Has Gone into Overdrive After This Latest News

1 | By Michael A. Robinson

The COVID-19 pandemic is and has been an unprecedented event, but there’s also something else to think about.

During this moment in history, we have never had a unified global effort quite like this to find an effective vaccine, and the convergence of technology and medicine that we have access to is allowing researchers to work on a vaccine at break-neck speed.

As of this writing, there are currently 28 COVID-19 vaccines in human trials, and the Trump Administration believes it will have an effective vaccine by 2021.

To get there, the federal government is spending an unprecedented $10 billion.

Now, I don’t have to tell you how explosive the biotech sector has been. Even just a whiff of a potential vaccine is sending stock prices through the roof. For example, the stock price for Altimmune Inc. (Alt), a clinical stage biopharma company, was trading for $1.78 on December 31, 2019. The company received approval to move its vaccine candidate into clinical trials, and the stock price is now above $20.

So think about what will happen when an effective vaccine is actually found.

Today, I wanted to provide you with free access to learn more about the company developing what I call the “Super Vaccine.”

Not only could the viable “Super Vaccine” bring COVID-19 to its knees, it could completely disrupt the $3.2 trillion health-care sector.

But to take part in this story and to learn how to grab your stake of the biotech revolution, you can’t wait.

I want to tell you all about it right here.

Cheers and good investing,

Michael A. Robinson

One Response to A “Super Vaccine” Deal Has Gone into Overdrive After This Latest News

Leave a Reply

Your email address will not be published. Required fields are marked *